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1ABSTRACT
Molecular and histopathologic characteristics of 
radioiodine-refractory papillary thyroid cancer
Ju Yeon Pyo
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor SoonWon Hong)
Radioiodine (RI) ablation after surgery with suppression of 
thyroid-stimulating hormone is an effective therapy for papillary thyroid 
cancer (PTC) and leads to an excellent prognosis. However, RI-refractory 
tumors are aggressive and have poor outcomes. Recently, studies of 
genetic abnormalities associated with signaling pathways related to PTC 
have shown that activation and mutation of telomerase reverse 
transcriptase (TERT) activity is associated with a poor outcome in PTC. 
We analyzed the proportion of mutations in BRAF V600E and the TERT
promoter, and compared the clinicopathological differences between 
RI-refractory and RI-responsive PTCs. Among 82 patients of 
RI-refractory PTC, we identified 26 cases for which formalin-fixed, 
paraffin-embedded tissue from the initial thyroidectomy were available. 
In the matched RI-responsive group without distant metastasis in the 5 
2years after surgery, 89 cases of PTC were collected. 
In the histopathological comparison of the two groups, RI-refractory 
PTCs showed a significant increase in small tumor clusters without 
fibrovascular cores (≥ 20% cut-off, especially in tumor centers), hobnail 
features (≥ 5% cut-off, especially in tumor centers), and in the 
height/width ratio of tumor cells (maximum ≥ 3). RI-refractory PTC 
showed significantly increased frequency of tumor necrosis, mitosis, 
lymph node metastasis, extrarthyroidal tumor extension, and involvement 
of resection margin. Interestingly, the nuclei of RI-refractory PTCs had 
an increased tendency to be located between the base and the middle area 
of tumor cells. TERT promoter mutations were found in 14/26 cases of 
RI-refractory PTC (53.8%, 13 TERT C228T, 1 TERT C250T) whereas
only 1/82 cases of RI-responsive PTC showed TERT promoter mutations 
(1.2%, TERT C228T). The BRAF V600E mutation was identified in more 
than 80% of cases in both groups. Coexistence of TERT promoter and 
BRAF mutations was found in 13/108 (12%) of all PTC cases. TERT
promoter mutations were significantly associated with clinicopathologic 
features mentioned above. Immunohistochemically, expression of NIS 
and TSHR was decreased in many cases of RI-refractory PTC. The 
expression of VEGF, VEGFR2, and NF-κB, known to be oncogenic 
3proteins, was somewhat lower in RI-refractory PTC than in 
RI-responsive PTC. Total loss of expression of PTEN was occasionally 
present in both groups. β-catenin, which is involved in the 
WNT-β-catenin pathway, showed cytoplasmic positivity in all cases. 
Comparison of immunohistochemical results for TERT and BRAF
mutations in all PTCs showed no correlation with either mutation, except 
for TSHR (TERT mutation). Four significant predictors of 
RI-refractoriness were identified: TERT mutation, height/width of tumor 
cells > 3, increased small clusters (≥ 20%), and necrosis. 
Our results suggest that RI-refractory PTCs may be strongly associated 
with TERT mutations and aggressive histopathologic features (small 
clusters and hobnail components), especially in tumor centers.
----------------------------------------------------------------------------------------
Key words: Papillary thyroid cancer, radioiodine-refractory, TERT
promoter mutations, micropapillary, hobnail, immunohistochemistry
4Molecular pathogenesis and histopathologic characteristics of 
radioiodine-refractory papillary thyroid cancer
Ju Yeon Pyo
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor SoonWon Hong )
I. INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common type of malignant 
thyroid neoplasm and its incidence has increased remarkably in recent years.1,2
Conventionally, the standard treatment for thyroid cancer is total or near-total 
thyroidectomy and adjuvant radioiodine (RI) ablation with suppression of 
thyroid stimulating hormone (TSH).3 Physiologically, thyroid follicular cells 
trap iodine using a sodium–iodide symporter (natrium iodide symporter, NIS), 
an energy-dependent transport system regulated by TSH4. Iodine is organified 
by thyroid peroxidase (TPO) at the apical surface of thyroid cells and then 
conjugated to thyroglobulin (Tg). Iodine is also trapped and organified by 
differentiated thyroid cancer (DTC) cells, as in thyrocytes.5 Iodine-131 (131I) is a 
β- and γ-emitting radionuclide and an effective therapeutic and imaging agent 
for DTCs. Dedifferentiated, poorly differentiated, and anaplastic thyroid tumor 
cell clones have lost the ability to trap iodine. Thus, RI is not effective for 
5detection or therapy of these tumors. Non-RI avid tumors have aggressive 
behavior and a poor prognosis.6 The classic treatment approach is highly 
effective for DTC, as DTC usually has an excellent prognosis with a 10-year 
disease-related survival of 85%.7 However, some patients with DTC develop an 
aggressive disease with distant metastases and loss of 131I avidity. Patients with 
RI-resistant DTC are usually not responsive to conventional chemotherapy and 
have a long-term overall survival of 10%.8 In addition, age, gender, tumor 
histological type, clinicopathological features, disease stage, presence of distant 
metastasis, and molecular genetic alterations may be responsible for the 
aggressive course of the disease. Molecular profiling of thyroid cancers is 
important for determination of prognosis, causes of treatment resistance, and 
targeted therapy options especially in RI-refractory patients.8
Recently, our understanding of the molecular pathogenesis of thyroid cancers 
has significantly improved, facilitating development of more effective targeted 
therapies, in particular tyrosine-kinase inhibitors. This mainly results from 
identification of the molecular alterations involved in thyroid cancer, including 
genetic and epigenetic alterations and dysregulation of signaling pathways,8
such as the RAS-RAF-MEK-MAPK-ERK pathway, the mitogen-activated 
protein kinase (MAPK) pathway, and the phosphatidyl-inositol3-kinase-Akt 
(PI3K-AKT) pathway,11 in addition to RET/PTC and TRK rearrangements.
These mutually exclusive mutations are found in more than 70% of papillary 
6thyroid carcinomas, including BRAF and RAS point mutations; RET/PTC and 
PAX8/PPARγ gene rearrangements; alteration of the MAPK, PI3K, p53, Wnt-β 
catenin, hypoxia inducible factor-1α (HIF1-α), and nuclear factor-κB (NF-κB) 
signaling pathways; and microRNA profiles and aberrant methylation.10-14
The BRAF V600E mutation is caused by a T1799A transversion at exon 15, 
resulting in the replacement of valine (V) with glutamic acid (E) at position 600 
of the protein, which results in expression of the BRAF-V600E mutant protein 
and causes activation of serine/threonine kinases.11,15 BRAF mutations are the 
most frequent genetic alteration in PTC and develop exclusively in PTC and 
PTC-derived anaplastic thyroid cancers. The mutations are known to be highly 
prevalent in PTC, at a frequency of 44–90%.16 A previous comprehensive 
multicenter study demonstrated a strong association of BRAF V600E with poor 
clinicopathologic outcomes of PTC, including aggressive pathological features, 
increased recurrence, loss of RI avidity associated with alteration of function of 
NIS, and treatment failures.11,17 All of the rearrangements and mutations 
increase BRAF activity and cause continuous induction of the MAPK signaling 
pathway.9
The PI3K/Akt signaling pathway plays major roles in several cellular events 
involved in growth, proliferation, and apoptosis.6 Activation of this pathway 
leads to tumorigenesis.18 The role of the PI3K/AKT pathway was first revealed 
by the finding that Cowden’s syndrome is caused by mutations or deletions of 
7the tumor suppressor gene PTEN. Activated Akt induces a signaling cascade by 
phosphorylating downstream protein effectors. Decreased expression or 
inactivation of the tumor suppressor gene product PTEN and activation by RAS
oncogenes have also been described to activate the PI3K/Akt signaling pathway 
and play a role in thyroid tumorigenesis.19 Combinations of some of these 
PI3K/Akt genetic alterations, as well as combination of these alterations with 
BRAF mutation, were shown to be present in more aggressive thyroid tumors. 
Genetic alterations that activate both the MAPK and PI3K/Akt pathways were 
also shown to be present.11
The MAPK pathway plays a major role in regulating cellular events, such as 
proliferation and survival, and is also known to affect tumorigenesis. Genetic 
and epigenetic alteration of the RTK (receptor tyrosine 
kinase)-RAS-RAF-MEK-MAPK-ERK pathway is very common in PTC.9
RET/PTC rearrangements and point mutations in RAS and BRAF have been 
shown to activate the MAPK pathway.10 In addition, secondary molecular 
events, such as hypomethylation and genome-wide hypermethylation20 and 
up-regulation of several oncogenic proteins, such as chemokines, NF-κB,21
HIF1-α, vascular endothelial growth factor (VEGF), matrix metalloproteinases 
(MMPs), MET, vimentin, prokineticin 1 (PROK1; also known as EG VEGF), 
prohibitin, thrombospondin 1 (TSP1), urokinase plasminogen activator (uPA) 
and its receptor (uPAR), and transforming growth factorβ1 (TGFβ1), drive 
8cancer cell growth, proliferation, and survival, together with tumor angiogenesis, 
invasion, and metastasis.9 NF-κB has recently been shown to play an important 
role in thyroid cancer, for its ability to control the proliferative and antiapoptotic 
signaling pathways of thyroid neoplastic cells. The oncogenic proteins 
RET/PTC, RAS, and BRAF can induce NF-κB activation in papillary, follicular, 
and medullary thyroid carcinomas. A number of NF-κB inhibitors have been 
demonstrated to induce antiproliferative effects and/or massive apoptosis, 
especially in combination with radio- or chemotherapy. 21,22 Thyroid tumors are 
associated with high vascularization and high levels of VEGF.23 Thyroid cell 
cultures show reduced proliferation when the VEGF pathway is blocked, thus 
demonstrating that antiangiogenic drugs have a direct antitumor activity on 
thyroid tumor cells.24
The WNT-β-catenin pathway has a well-established role in the regulation of 
cell growth and proliferation. Up-regulated β-catenin is translocated into the 
nucleus where it triggers transcription of various tumor-promoting genes. Point 
mutations in exon 3 of CTNNB1 have been found in 66% of ATCs and 25% of 
poorly differentiated carcinomas, although not in DTCs. Thus, the 
WNT–β-catenin pathway seems to have a particularly important role in thyroid 
tumor aggressiveness.25 Interestingly, RET–PTC can activate the 
WNT–β-catenin pathway by activating the PI3K–AKT pathway and also by 
directly phosphorylating β-catenin in thyroid cancer cells.9
9The main function of follicular thyroid cells is to use iodide to synthesize 
thyroid hormone. Iodide is transported into the cell through sodium–iodide 
symporters (NIS) located in the basal membrane. NIS is up-regulated by 
TSH-mediated activation of TSHR.26 The iodide-handling machinery is often 
impaired, particularly in advanced thyroid cancers, making RI treatment 
ineffective.9 Aberrant activation of the MAPK pathway plays an important role 
in the impairment of the iodide-handling machinery.16 BRAF V600E mutation is 
associated with the loss of RI avidity and with RI treatment resistance in PTC.
In addition, BRAF V600E mutation is highly prevalent (78–95%) in recurrent 
RI-refractory PTC28 but not in primary PTC (45%).27 Several studies have 
reported BRAF V600E mutation, accompanied by decreased or absent 
expression of thyroid iodide-handling genes such as NIS, TSHR, TPO, TG, and 
SLC26A4, in thyroid cancer.28-30 NIS expression is significantly lower in the tall 
cell and diffuse sclerosing variants of PTC than in conventional PTC. Due to 
their low NIS expression, the tall cell and diffuse sclerosing variants of PTC 
require higher cumulative doses of radioactive iodine therapy to improve the 
prognosis.31 Activation of the PI3K-AKT pathway has also been shown to 
down-regulate the iodide-handling machinery. Inhibition of the PI3K-AKT 
pathway induces NIS expression32 and also induces the expression of TSHR, 
TPO, and TG, and is enhanced by treatment with histone deacetylase inhibitors,
in human thyroid cancer cells. The involvement of both the MAPK and 
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PI3K-AKT pathways in the silencing of thyroid iodide-handling genes is 
consistent with the accumulation of genetic alterations in both pathways as 
thyroid tumors progress, during which loss of RI avidity increases.9
Most recently, activation of telomerase, especially mutation and increase of 
telomerase reverse transcriptase (TERT) activity, was reported in thyroid cancer 
and several human solid tumors. 33-39 Telomerase synthesizes tandem repeats of 
TTAGGG at the ends of chromosomes in vertebrates and prevents chromosome 
shortening and loss of genetic information. A C>T mutation in the TERT
promoter region increases TERT transcriptional activity.40 Mutations in the 
TERT promoter, such as –chr5:1 295 228C>T (termed TERT C228T) and chr5:1 
295 250C>T (termed TERT C250T), transform DTC to undifferentiated 
anaplastic carcinoma.41 The frequency of TERT promoter mutation varies 
depending on the histologic subtype or differentiation of thyroid cancer 
(7.5–25%),39 and it causes more aggressive behavior with poorer outcome in 
PTCs and is more frequent in BRAF-mutated tumors.33,34
In this study, we focused on well-known genetic abnormalities associated with 
signaling pathways and the related histopathologic features known in PTCs. We 
performed comparative analysis of the molecular changes and histopathologic 
differences between RI-responsive and RI-refractory PTCs. We aimed to 
identify clinicopathological features associated with the prognosis and treatment 
of RI-refractory PTCs.
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II. MATERIALS AND METHODS
1. Case selection and clinicopathologic review
Formalin-fixed, paraffin-embedded (FFPE) tissue samples were obtained from 
PTC specimens obtained from patients who underwent thyroidectomy with RI 
and further treatment at Gangnam Severance Hospital (Seoul, Korea) between 
July 2006 and October 2014. Patient information and clinicopathological 
parameters were reviewed for 15,000 cases of PTC and analyzed retrospectively
using the electronically available clinical data. A patient was considered 
resistant to the RI ablation therapy when at least one tumor lesion was observed 
that did not show uptake of RI, or when the lesion radiologically progressed in 
the first 12 months post-radioiodine administration, or when the patient had 
persistent disease following the administration of an accumulated dose of 
radioactive iodine of >600 mCi.42 For this study, 82 cases of PTC were 
determined to belong to the RI-refractory group, which developed recurrence or 
distant metastasis following the administration of an accumulated dose of 
radioactive iodine of >600 mCi. After case sampling of the RI-resistant group, 
89 cases of PTC were selected as age- and gender-matched case-controls 
without distant metastasis during 5 years and were sampled as the RI-responsive 
group. Among the RI-refractory group, FFPE tissue from initial thyroidectomy 
samples was obtainable in 26 cases.
A histopathologic review was performed on primary surgically removed 
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thyroid tissue and as much additional tissue as possible was obtained from both 
groups. According to the criteria recommended by World Health Organizing 
Classification of Tumors,43 PTC was classified and staged according to AJCC 
Cancer Staging Manual, 7th edition.44
2. Mutational analysis using molecular studies
Sections (10 μm) were cut from the FFPE tissue blocks. DNA was extracted 
from these sections using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The extracted DNA was 
used in molecular assays using PNA-mediated clamping PCR and 
pyrosequencing methods. 
PNA-mediated clamping PCR was performed using the PNA Clamp BRAF 
Mutation Detection kit (Panagene, Daejeon, Korea).45 The real-time PCR 
reaction for the PNA clamping PCR was performed using a CFX 96 Real-time 
PCR System (Bio-Rad, Pleasanton, CA). PCR cycling conditions consisted of a 
5 min hold at 94°C, followed by 40 cycles of 94°C for 30 sec, 70°C for 20 sec, 
63°C for 30 sec, and 72°C for 30 sec. The Δ Ct (ΔCt) value was calculated by 
subtracting the Ct value of a tested sample from the standard Ct value of the 
clamping control sample ([Standard Ct] − [Sample Ct] = ΔCt). A cut-off ΔCt 
value ≥ 2 was considered positive for the BRAF mutation (Figure 1). 
Pyrosequencing was performed for further analysis of TERT promoter 
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mutations. Pyrosequencing of TERT promoter mutations was performed with a 
sequencing primer (5′-ACCCCGCCCCGTCCC GACCCC-3′) on a Pyromark 
Q24 (Qiagen) after PCR amplification with the following primer pair (forward 
5′-GTCCTGCCCCTTCACCTT-3′ and reverse 5′-biotin-CAGCGCTGCCTG
AAACTC-3′) on a PCR C1000 Thermal cycler (Bio-Rad). The pyrogram output 
was analyzed using the PyroMark Q24 software (Qiagen) to determine the 
percentage of mutant versus wild-type DNA, according to relative peak height 
(Figure 2).
BRAF Negative control
BRAF Test
Figure 1. Results of PNA-mediated clamping PCR for BRAF mutatio
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Figure 2. Results of pyrosequencing of TERT promoter mutation
3. Construction of tissue microarray (TMA)
For the immunohistochemical (IHC) study, TMA blocks were made using 
representative, well-fixed tumor samples (two cores, 2 mm in diameter) and 
normal tissue samples (1 core, 2 mm in diameter) from the FFPE blocks
4. Immunohistochemistry
Immunohistochemistry of samples from both PTC groups was performed 
using 4-μm thick FFPE tissue sections on silane-coated slides. After drying the 
slides in an oven for 1 hour, immunostaining was performed automatically 
using a Ventana BenchMark XT Autostainer (Ventana Medical Systems, 
C>T
C250T C228T
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Tucson, AZ, USA) and an OptiVew DAB IHC Detection kit (Ventana Medical 
Systems). The protocol consisted of a 48-minute antigen-retrieval step in CC1 
(Cell conditioning); a 10-minute endogenous peroxidase blocking step in 
peroxide block; a 16-minute incubation in 42℃ with primary antibodies, 
including NIS (monoclonal mouse, 1:50, Thermo, USA), TSHR (4C1/E1/E8, 
mouse monoclonal, 1: 100, Abcam Inc. Cambridge, MA), VEGF (C-1, mouse 
monoclonal, 1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), VEGFR2 
(55B11, rabbit monoclonal, 1:200, Cell Signaling Technology, Beverly, MA), 
NF-κB p65 (F-6, mouse monoclonal, 1: 1000, Santa Cruz Biotechnology, INC., 
Santa Cruz, CA), β-catenin (β-catenin-1, mouse monoclonal, 1:100, DAKO, 
Carpinteria, CA) and PTEN (6H2.1, mouse monoclonal, 1: 100, Biocare 
Medical, Walnut Creek, CA).
5. Interpretation of immunohistochemistry 
Nuclear and cytoplasmic staining for NIS and TSHR, cytoplasmic staining for
NF-κB, VEGF, and PTEN, cytoplasmic staining of vascular endothelial cells for 
VEGFR2, and nuclear staining for β-catenin were considered positive and 
evaluated by light microscopy. The results of IHC staining were defined by 
intensity and volume. “Volume” was the proportion of stained cells and 
“intensity”, was classified as 0 (negative), 1 + (weak), 2+ (moderate), and 3+ 
(strong). 
16
Modified scores for immunohistochemistry are reported as follows: 0, no 
stained cells; 1, when 1–49% of tumor cells were stained with weak intensity; 2, 
when ≥ 50% of tumor cells were stained with weak intensity; 3, when 1–49% of 
tumor cells were stained with moderate intensity; 4, when ≥ 50% of tumor cells 
were stained with moderate intensity; 5, 1–49% of tumor cells were stained with 
strong intensity; and 6, when ≥ 50% of tumor cells were stained with strong 
intensity. Loss of expression of PTEN was scored in reverse order.
6. Statistical analysis
Statistical analysis of data was performed using the SPSS software (version 
21.0; SPSS Inc., Chicago, IL, USA). The t and χ2 tests were used to analyze 
differences between two groups for each variable. Correlation analysis was 
performed between variables. Logistic regression was performed to assess odds 
ratios (OR) and 95% confidence intervals (CI) for radioiodine-refractoriness 
with multiple variables including clinicopathologic features and results of 
mutation analysis. All P values were 2-sided and P < 0.05 was considered 
statistically significant.
17
III. RESULTS
1. Clinicopathologic characteristics of RI-refractory and RI-responsive 
PTCs
The RI-refractory and RI-responsive groups differed significantly in 
clinicopathologic features. Histologically, a significantly increased proportion 
of small clusters/micropapillae without fibrovascular cores (Figure 3A and 3C) 
and/or hobnail components were observed in both the periphery and center of 
tumors in RI-refractory PTCs (Figure 3C), and the maximum height/width ratio 
of tumor cells was ≥3 in this group (Figure 4A). Tumor necrosis and mitosis are 
comparatively rare in differentiated papillary carcinoma, but they were observed 
in RI-refractory PTCs (Figure 3E). Interestingly, the location of tumor cell 
nuclei in RI-refractory PTCs was mostly middle to base (Figure 4A), but apex 
to middle in RI-responsive PTCs (Figure 4B). RI-responsive PTCs showed 
occasional areas of small clusters of tumor cells or single cells at tumor 
peripheries; these were mostly cuboidal to columnar in appearance and the 
location of nuclei was middle to apical (Figure 3B and 3D). 
Clinicopathologically, RI-refractory PTCs showed significantly increased 
frequency of extrathyroidal extension of tumor and involvement of the resection 
margin with lymph node metastasis at initial diagnosis (Table 1).
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Figure 3. Representative histologic features of radioiodine-refractory papillary 
thyroid cancers. (A, C, E) and radioiodine-responsive papillary thyroid cancers
(B, D, F). Both types of tumors show classic papillary architecture with varying 
degrees of small clusters/micropapillae without fibrovascular cores (arrow) or 
discohesive single cells. Tumor necrosis is comparatively rare, but remarkably 
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increased in the radioiodine-refractory group rather than the radioiodine-
responsive group (E).
Figure 4. Histologic features of classic papillary pattern and hobnail pattern of 
papillary thyroid cancers (A–D). In some radioiodine-refractory cases, tumor 
cells have longer and more slender papillary structure, with increased 
height/width ratio (≥ 3) and base to middle location of nuclei (A) or a hobnail 
pattern, with elongated nuclei within the cell apex (C and D). Tumor cells of 
radioiodine-responsive cases reveal mostly cuboidal or columnar in appearance, 
and nuclei were located in the middle to apex of the cell (B).
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Table 1. Clinicopathologic features of radioiodine-refractory and 
radioiodine-responsive papillary thyroid cancers
Clinicopathologic features
RI-refractory 
PTC (N = 26)
RI-responsive 
PTC (N = 82)
P-value
Gender (%) Male 13 (50) 37 (45.1) 0.664
Female 13 (50) 45 (54.9)
Age at diagnosis Median, yr 
(Range)
58 (16-71) 51 (18-71)   0.063*
Histologic type 
(%)
Conventional 23 (88.5) 76 (92.7) 0.231
Diffuse-sclerosing 2 (7.7) 2 (2.4)
Follicular 0 3 (3.7)
Hurthle cell 1 (3.8) 0
Cribriform-morular 0 1 (1.2)
Tall cell 0 0
Histologic features
Small clusters 
(%)1
< 20% 9 (34.6) 76 (92.7) <0.001
≥ 20% 17 (65.4) 6 (7.3)
Small clusters        
in tumor center
Absent 5 (19.2) 39 (47.6) 0.01
Present 21 (80.8) 43 (52.4)
Hobnail feature 
(%)
< 5% 5 (19.2) 46 (56.1) 0.001
≥ 5% 21 (80.8%) 36 (43.9)
Hobnail feature      
in tumor center
Absent 18(69.2) 72 (87.8) 0.036† 
Present 8 (30.8) 10 (12.2)
Tall cell feature
(%)2
<10% 12 (46.2) 79 (96.3) <0.001†
≥ 10%, < 50% 14 (53.8) 3 (3.7)
Necrosis Absent 10 (38.5) 81 (98.8) <0.001†
Present 16 (61.5) 1 (1.2)
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Clinicopathologic features
RI-refractory 
PTC (N = 26)
RI-responsive 
PTC (N = 82)
P-value
Height/Width 
ratio of tumor cell 
(%)
Maximum < 3 12 (46.2) 76 (92.7) <0.001†
Maximum ≥ 3 14 (53.8) 6 (7.3)
Location of      
nuclei (%)3
Apex 2 (9.5) 19 (90.5) 0.013† 
0.016‡Middle 22 (25.9) 63 (74.1)
Base 2 (100) 0
Mitosis Absent 14 (53.8) 80 (97.6) <0.001† 
Present 12 (46.2) 2 (2.4)
Tumor 
multifocality
Single 9 (34.6) 46 (56.1) 0.056
Multifocal 17 (65.4) 36 (43.9)
Tumor size (%) ≤2 ㎝ 10 (38.5) 66 (80.5) < 0.001
>2 ㎝, ≤4 ㎝ 9 (34.6) 14 (17.1)
>4 ㎝ 7 (26.9) 2 (2.4)
Lymph node
metastasis (%)
Absent 2 (7.7) 23 (28) 0.032
Present 24 (92.3) 59 (72)
Extrathyroidal 
extension
Absent 2 (7.7) 23 (28) 0.032
Present 24 (92.3) 59 (75.9)
Resection margin Negative 17 (65.4) 80 (97.6) <0.001† 
Positive 9 (34.6) 2 (2.4)
Tumor margin Expanding 1 (3.8) 18 (22.5) 0.038† 
Infiltrative 25 (96.2) 62 (77.5)
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Clinicopathologic features
RI-refractory 
PTC (N = 26)
RI-responsive 
PTC (N = 82)
P-value
Stage (%) I 5 33 < 0.001
II 1 0
III 3 32
IVA 13 17
IVB 1 0
IVC 3 0
* Mann-Whitney test, † Fisher's exact test, ‡ Linear-by-Linear Association; 
1small tumor clusters composed of micropapillae without fibrovascular cores; 2 
the tumor cells show a granular eosinophilic cytoplasm with a height is at least 
triple their width (< 50% of tumor); 3The main location of nuclei within tumor 
cell; RI, radioiodine; PTC, papillary thyroid cancer.
2. BRAF V600E and TERT mutation results 
A. Individual incidence of molecular variables in each groups
The TERT promoter mutation (P < 0.001) was found in 14/26 cases of 
RI-refractory PTC (53.8%, 13 TERT C228T, 1 TERT C250T) but in only 1/82 
cases of RI-responsive PTC (1.2%, in TERT C228T). The BRAF V600E 
mutation was found in more than 80% of cases in both groups (21/26, 80.8% in 
the RI-refractory group and 67/82, 81.7% in the RI-responsive group) (Table 2).
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Table 2. Incidences of TERT promoter mutations and BRAF V600E mutation in
radioiodine-refractory and radioiodine-responsive papillary thyroid cancers
RI-refractory 
PTC
RI-responsive 
PTC
Total P-value*
Mutation (N = 26) (N = 82) (N = 108)
TERT promoter (%) 14 (53.8) 1 (1.2) 15 (13.9) <0.001
Type of Mutation
C250T 1 (3.8) 0 1 (0.9) 0.241
C228T 13 (50) 1 (1.2) 14 (13) <0.001
BRAF V600E (%) 21 (80.8) 67 (81.7) 88 (81.5) 1
* Fisher's exact test; RI, radioiodine; PTC, papillary thyroid cancer.
B. Combined incidence of molecular variables in each groups
Coexistence of TERT promoter and BRAF mutations was found in 13/108 
(12%) in all cases of PTC, either RI-refractory or RI-responsive. Coexistence of 
two mutations was observed in only 1 case of RI-responsive PTC; in 18 cases, 
no mutation was identified (Table 3).
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Table 3. Combined incidences of TERT promoter mutations and BRAF V600E 
mutation in radioiodine-refractory and radioiodine-responsive papillary thyroid 
cancers
Total
TERT C228T TERT C250T
Wild Mutant Wild Mutant
RI-refractory PTC 26 13 13 25 1
BRAF-Wild 5 3 2 5 0
BRAF-Mutant 21 10 11 20 1
RI-responsive PTC 82 81 1 82 0
BRAF-Wild 15 15 0 15 0
BRAF-Mutant 67 66 1 67 0
RI, radioiodine; PTC, papillary thyroid cancer.
C. Relationship between clinicopathologic features and expressions of 
molecular variables
In the analysis of correlation between molecular changes and clinicopathologic 
features, TERT promoter mutations were similarly associated with 
clinicopathologic features including small clusters, hobnail component, 
height/width of tumor cells, necrosis, mitosis and resection margin; the 
significance of each association is reported in (Table 4).
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Table 4. Relationship between clinicopathologic features and TERT promoter 
mutation or BRAF V600E mutation in papillary thyroid cancers
TERT all mutations BRAF V600E
Total PTC
(N = 108)
Wild
(N = 93)
Mutant
(N = 15)
P- value
Wild
(N = 20)
Mutant
(N = 88)
P- value
Gender (%)
Male
45
(48.4)
5
(33.3)
0.278
7
(35)
43
(48.9)
0.262
Female
48
(51.6)
10
(66.7)
13
(65)
45
(51.1)
Median age at 
diagnosis (range)
51
(17-71)
62
(16-71)
0.007*
50.5
(17-70)
52
(16-71)
0.519*
Histologic type (%)
Conventional
85
(91.4)
14
(93.3)
0.366†
16
(80)
83
(94.3)
0.078†
Diffuse-
sclerosing
4
(4.3)
0 2
(10)
2
(2.3)
Follicular
3
(3.2)
0 1
(5)
2
(2.3)
Hurthle cell 0
1
(6.7)
0
1
(1.1)
Cribriform-
morular
1 
(1.1)
0 1 
(5)
0
Tall cell 0 0 0 0
Histologic features
Small clusters  (%)1
< 20%
81 
(87.1)
4 
(26.7)
<0.001† 16
(80)
69 
(78.4)
1†
≥ 20%
12 
(12.9)
11 
(73.3)
4 
(20)
19
(21.6)
Small clusters in tumor center
Absent
43 
(46.2)
1 
(6.7)
0.004 9 
(45)
35 
(39.8)
0.668
Present
50 
(53.8)
14
(93.3)
11 
(55)
53 
(60.2)
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TERT all mutations BRAF V600E
Total PTC
(N = 108)
Wild
(N = 93)
Mutant
(N = 15)
P- value
Wild
(N = 20)
Mutant
(N = 88)
P- value
Hobnail feature (%)
< 5%
49 
(52.7)
2
(13.3)
0.005 9 
(45)
42
(47.7)
0.825
≥ 5%
44 
(47.3)
13
(86.7)
11
(55)
46
(52.3)
Hobnail feature in tumor center
Absent
82 
(88.2)
8
(53.3)
0.003† 17 
(85)
73 
(83)
1†
Present
11 
(11.8)
7
(46.7)
3 
(15)
15
(17)
Tall cell feature (%)2
<10%
85 
(91.4)
6
(40)
0.001† 17 
(85)
74 
(84.1)
1†
≥ 10%
8 
(8.6)
9
(60)
3 
(15)
14 
(15.9)
Height/Width ratio of tumor cell (%)
Max. < 3
81
(87.1)
7
(46.7)
0.001† 16 
(80)
72
(81.8)
1†
Max. ≥ 3
12 
(12.9)
8
(53.3)
4
(20)
16
(18.2)
Location of nuclei (%)3
Apex   
19 
(90.5)
2 
(9.5)
0.287‡ 5 
(23.8)
16 
(76.2)
0.392‡
Middle
73 
(85.9)
12 
(14.1)
15 
(17.6)
70 
(82.4)
Base
1 
(50)
1 
(50)
0 2 
(100)
Necrosis
Absent
85 
(91.4)
6 
(40)
<0.001† 17
(85)
74 
(84.1)
1†
Present
8 
(8.6)
9
(60)
3 
(15)
14 
(15.9)
Mitosis
Absent
84 
(90.3)
10 
(66.7)
0.025† 17 
(85)
77 
(87.5)
0.721†
Present
9 
(9.7)
5
(33.3)
3 
(15)
11
(12.5)
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TERT all mutations BRAF V600E
Total PTC
(N = 108)
Wild
(N = 93)
Mutant
(N = 15)
P- value
Wild
(N = 20)
Mutant
(N = 88)
P- value
Tumor multifocality
Single
50 
(53.8)
5 
(33.3)
0.142 11
(55)
44 
(50)
0.686
Multifocal
43 
(46.2)
10
(66.7)
9
(45)
44
(50)
Tumor size (%)
≤2 ㎝
72
(77.4)
4
(26.7)
<0.001† 12
(60)
64
(72.7)
0.024†
>2 ㎝, ≤4 ㎝
18
(19.4)
5
(33.3)
3
(15)
20
(22.7)
>4 ㎝
3
(3.2)
6
(40)
5
(25)
4
(4.5)
Lymph node metastasis (%)
Absent
24
(25.8)
1
(6.7)
0.184† 8
(40)
17
(19.3)
0.075†
Present
69
(74.2)
14
(93.3)
12
(60)
71
(80.7)
Extrathyroidal extension
Absent
24
(25.8)
1
(6.7)
0.184† 5
(25)
20
(22.7)
0.777†
Present
69
(74.2)
14
(93.3)
15
(75)
68
(77.3)
Resection margin
Absent 87
(93.5)
10 
(66.7)
0.007† 18 
(90)
79 
(89.8)
1†
Positive 6 
(6.5)
5 
(33.3)
2 
(10)
9 
(10.2)
Tumor margin
Expanding 19
(20.9)
0 0.067† 6 
(30)
13 
(15.1)
0.191†
Infiltrative 72 
(79.1)
15 
(100)
14
(70)
73 
(84.9)
Stage (%)
I 36 2 <0.001† 8 30 0.983†
II 0 1 0 1
III 35 1 7 29
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TERT all mutations BRAF V600E
Total PTC
(N = 108)
Wild
(N = 93)
Mutant
(N = 15)
P- value
Wild
(N = 20)
Mutant
(N = 88)
P- value
IVA 19 10 5 24
IVB 1 0 0 1
IVC 2 1 0 3
* Mann-Whitney test; † Fisher's Exact test; ‡ Linear-by-Linear Association; 
1small tumor clusters composed of micropapillae without fibrovascular cores; 2 
the tumor cells show a granular eosinophilic cytoplasm with a height is at least 
triple their width (< 50% of tumor); 3The main location of nuclei within tumor 
cell; PTC, papillary thyroid cancer.
3. Immunohistochemical stain results
A. Individual immunohistochemical stain results in each groups 
Immunohistochemically, expression of NIS and TSHR, which are involved in 
the MAPK pathway, was markedly decreased in many cases of RI-refractory 
PTC (P < 0.05). Expression of VEGF, VEGFR2, and NF-κB, which are known 
to be oncogenic proteins that are up-regulated in PTC, was somewhat lower in 
RI-refractory PTC than in RI-responsive PTC (P < 0.05). Total loss of PTEN 
expression was occasionally observed in both RI-refractory PTC (26.9%) and 
RI-responsive PTC (15.9%). β-catenin, which is involved in the WNT-β-catenin 
pathway, showed cytoplasmic positive reactivity in all PTCs (Table 5). 
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Table 5. Individual immunohistochemical stain results in radioiodine-refractory 
and radioiodine-responsive papillary thyroid cancers
Immunohistochemistry
(N = 108)
RI-refractory PTC RI-responsive PTC P-value
(N = 26) (N = 82)
NIS <1+, 50% 12 (46.2) 21 (25.6) 0.048
≥1+, 50% 14 (53.8) 61 (74.4)
TSHR <2+ 17 (65.4) 21 (25.6) 0.000
≥2+ 9 (34.6) 61 (74.4)
VEGF <3+, 50% 17 (65.4) 32 (39%) 0.019
≥3+, 50% 9 (34.6) 50 (61%)
VEGFR2 <2+* 11 (42.3) 16 (19.5) 0.019
≥2+ 15 (57.7) 66 (80.5)
NF-κB <1+, 50% 9 (34.6) 11 (13.4) 0.022† 
≥1+, 50% 17 (65.4) 71 (86.6)
PTEN negative 7 (26.9) 13 (15.9) 0.248† 
positive 19 (73.1) 69 (84.1)
† Fisher's exact test; Chi-squared test: not annotated; intensity of immunehisto 
chemical staining: 0, 1+, 2+, 3+, *2+: ≥ 30% in stroma; RI, radioiodine; PTC, 
papillary thyroid cancer; NIS, sodium iodide symporter; TSHR, thyroglobulin 
stimulating hormone receptor; VEGF, vascular endothelial cell growth factor; 
VEGFR2, vascular endothelial cell growth factor receptor 2; NF-κB, nuclear 
factor kappa-light-chain-enhancer of activated B cells.
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B. Relationship between immunohistochemical results and expressions of 
molecular variables
Comparative analysis of immunohistochemical results with TERT and BRAF
mutations in all PTC revealed no correlation with TERT and BRAF mutation
status, except for TSHR (P = 0.03, TERT mutation) in all PTC (Table 6).
C. Relationship between clinicopathologic features and immunohisto
chemical results
In Spearman correlation analysis between immunohistochemical and 
histopathologic features, negative correlations were observed between NIS and 
small clusters (r = - 0.212, P = 0.027), NIS and hobnail features (r = -0.249, P =
0.009), TSHR and height/width of tumor cells (r = - 0.279, P = 0.003), PTEN 
and small cluster in tumor centers (r = - 0.232, P = 0.016), VEGFR2 and small 
clusters (r = - 0.272, P = 0.004), VEGFR2 and small clusters in tumor centers (r
= - 0.308, P = 0.001), and VEGF and hobnail features in tumor centers (r = -
0.197, P = 0.042). Positive intercorrelations were observed between VEGF and 
NF-κB (r = 0.252, P = 0.009), hobnail features and hobnail features in tumor 
centers (r = 0.550, P < 0.001), hobnail features and small clusters (r = 0.662, P 
< 0.001), hobnail features and small clusters in tumor centers (r = 0.537, P <
0.001), small clusters and height/width of tumor cells (r = 0.351, P < 0.001), 
small clusters in tumor centers and height/width of tumor cells (r = 0.247, P =
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0.010). The Mann-Whitney test and Fisher’s exact test confirmed the 
significance of these results. Significant associations between histologic 
features and immunohistochemical results were observed in the RI-refractory 
and RI-responsive groups (Figure 5).
4. Combined utility of variables for predicting radioiodine-refractoriness
Prior to conducting the logistic regression analysis of RI-refractoriness in PTC, 
the sensitivity and specificity for predicting RI-refractory PTC were calculated. 
Among the sixteen variables, presence of necrosis and TERT mutation had high 
specificity (99%) and high accuracy (89.8% and 88%, respectively). Small 
clusters (≥10%), small clusters in tumor centers, and hobnail features had high 
sensitivity (88%, 81%, and 81%, respectively). Combined with other variables, 
especially with necrosis, both sensitivity and specificity increased. Other sets of 
variables, such as presence of TERT mutation or mitosis, were also analyzed, 
but no significant associations were observed (Table 7).
In the logistic regression analysis, fourteen variables were incorporated, and 
useful predictors of RI-refractoriness were selected by likelihood ratio, using a 
backward stepwise method. Four features that can be used to predict of 
RI-refractoriness were identified: TERT mutation, height/width of tumor cells
≥ 3, increased small clusters (≥ 20%), and necrosis (Table 8).
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Table 6. Relationship between immunohistochemical results and expressions of 
mutations of TERT and BRAF V600E
TERT all mutations BRAF V600E
Immunohistochemistry Wild Mutant Wild Mutant
            (N = 108) (N = 93) (N = 15) P- value (N = 20) (N = 88) P-value
NIS <1+, 50%
26
(28)
7
(46.7)
0.225†
8
(40)
25
(28.4)
0.310
≥1+, 50%
67
(72)
8
(53.3)
12
(60)
63
(71.6)
TSHR <2+
29
(31.2)
9
(60)
0.030
9
(45)
29
(33)
0.309
≥2+
64
(68.8)
6
(40)
11
(55)
59
(67)
VEGF < 3+
32
(34.4)
6
(40)
0.674
10
(50)
28
(31.8)
0.124
≥3+
61
(65.6)
9
(60)
10
(50)
60
(68.2)
VEGFR2 <2+*
21
(22.6)
6
(40)
0.197†
4
(20)
23
(26.1)
0.567
≥2+
72
(77.4)
9
(60)
16
(80)
65
(73.9)
NF-κB <3+, 50%
53
(57)
10
(66.7)
0.481
16
(80)
47
(53.4)
0.029
≥3+, 50%
40
(43)
5
(33.3)
4
(20)
41
(46.6)
PTEN Negative
16
(17.2)
4
(26.7)
0.472†
6
(30)
14
(15.9)
0.199†
Positive
77
(82.8)
11
(73.3)
14
(70)
74
(84.1)
† Fisher's exact test, Chi-squared test: not annotated; intensity of immunohisto
chemistry: 0, 1+, 2+, 3+, *2+: ≥ 30% in stroma; NIS, sodium iodide symporter; 
TSHR, thyroglobulin stimulating hormone receptor; VEGF, vascular 
endothelial cell growth factor; VEGFR2, vascular endothelial cell growth factor 
receptor 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B 
cells.
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SC
(≥10%)
SC
in 
center
Hobnail 
feature 
(≥5%)
Hobnail 
feature 
in 
center 
≥3
Height/
Width 
ratio
Mitosis Necrosis
NIS
★ ★ ● ● ●
☆☆ ☆☆
TSHR
★ ★ ● ★ ● ★ ●
☆
VEGF
● ★ ●
☆☆
☆☆
○○
VEGFR2 
★ ★
☆☆
NF-κB
●
☆ ○ ☆☆
PTEN
★ ○○
Spearman correlation in all PTC (N = 108)
Spearman correlation in RI-refractory PTC (N = 26)
Spearman correlation in RI-responsive PTC (N = 82)
Figure 5. Relationship between clinicopathologic features and immunohisto 
chemical results (★Mann-Whitney test in all papillary thyroid cancers (PTC); 
☆Mann-Whitney test in radioiodine refractory PTC; ☆☆Mann-Whitney test in 
radioiodine responsive PTC; ●Fisher's exact test or Chi-squared test in all PTC;
○Fisher's Exact test or Chi-squared test in radioiodine refractory PTC;
○○Fisher's exact test or Chi-squared test in radioiodine responsive PTC;
Immunohistochemistry score, -:0, 1+: 1–2 (≥ 50%), 2+: 3–4 (≥ 50%), 3+: 5–6 
(≥ 50%), cut–off value: NIS (<1+, 50%), TSHR (< 2+), VEGF (< 3+), VEGFR2 
(< 2+), NF-κB (< 3+, 50%), PTEN (negative); SC, small tumor clusters 
composed of micropapillae without fibrovascular cores; NIS, sodium iodide 
symporter; TSHR, thyroglobulin stimulating hormone receptor; VEGF, vascular 
endothelial cell growth factor; VEGFR2, vascular endothelial cell growth factor 
receptor 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B 
cells.)
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Table 7. Sensitivity and specificity of histopathologic features and mutation in 
radioiodine-refractory papillary thyroid cancers
Histopathologic features
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
Necrosis 62 99 89.8 
TERT mutation 54 99 88.0 
Small clusters (≥ 20%)1 65 93 86.1 
Mitosis 46 98 85.2 
Tall cell feature
(≥ 10%, < 50%)2
54 96 86.1
Height/Width ratio in tumor 
cells (maximum ≥ 3)
54 93 83.3 
Small clusters (≥ 10%) 88 71 75.0 
NF-kB (< 1+, 50%) 35 87 74.1 
Hobnail feature in center 31 88 74.1 
TSHR (< 2+) 65 74 72.2 
VEGFR2 (< 2+) 42 80 71.3 
PTEN (Negative) 27 84 70.4 
NIS (< 1, 50%) 46 74 67.6 
Hobnail feature 81 56 62.0 
VEGF (< 3+, 50%) 65 61 62.0 
Small clusters in center 81 48 55.6 
BRAF V600E mutation 77 18 32.4 
Necrosis + TERT mutation 81 98 93.5 
TERT mutation + Mitosis 81 96 92.6 
Necrosis + Mitosis 77 96 91.7 
Necrosis + H/W3 88 91 90.7 
Mitosis + SC20 85 90 88.9 
TERT mutation + H/W3 77 91 88.0 
Necrosis + SC20 77 91 88.0 
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Histopathologic features
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
H/W3 + SC20 92 85 87.0 
Necrosis + Mitosis + TERT
mutation
96 88 89.8 
TERT mutation + H/W3 + 
Necrosis + Mitosis
96 88 89.8 
TERT mutation + H/W3 + 
Necrosis + SC20
96 83 86.1 
TERT mutation + H/W3 + 
Necrosis + SC20 + Mitosis
100 80 85.2 
TERT mutation + H/W3 + SC10 
+ TSHR + NFKB
100 43 56.5 
TERT mutation + SC10 + TSHR 
+ NFKB
100 46 59.3 
1small tumor clusters composed of micropapillae without fibrovascular cores; 2 
the tumor cells show a granular eosinophilic cytoplasm with a height is at least 
triple their width (< 50% of tumor); NF-κB, nuclear factor kappa-light 
-chain-enhancer of activated B cells; TSHR, thyroglobulin stimulating hormone 
receptor; VEGFR2, vascular endothelial cell growth factor receptor 2; VEGF, 
vascular endothelial cell growth factor; NIS, sodium iodide symporter; H/W3,
height//width ratio in tumor cells (maximum ≥ 3); SC20, small clusters (≥
20%); SC10, small clusters (≥ 10%).
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Table 8. Logistic regression analysis on radioiodine-refractoriness in papillary 
thyroid cancers (N = 108)
Variables B S.E p-value Odd Ratio 95% C.I
Univariate regression
Small clusters
(≥ 20%)
3.175 0.591 < 0.001 23.926 7.51-76.26
Small clusters
(≥ 10%)
2.919 0.660 < 0.001 18.528 5.08-67.56
Small clusters 
in center
1.337 0.545 0.014 3.809 1.31-11.08
Hobnail feature
(≥ 5%)
1.680 0.545 0.002 5.367 1.84-15.62
Hobnail features
in center
1.163 0.543 0.032 3.200 1.11-9.27
Tall cell feature 
(≥ 10%)
1.885 0.310 < 0.001 6.583 0.008-0.130
Necrosis (present) 4.864 1.084 < 0.001 129.6 15.49-1084.489
Mitosis 
(≥ 1/10HPF)
3.535 0.817 < 0.001 34.286 6.92-169.99
Height/Width 
ratio of tumor cell    
(maximum ≥ 3)
2.693 0.578 < 0.001 14.778 4.56-45.92
TERT mutation 4.549 1.080 < 0.001 94.5 11.37-785.25
BRAF V600E
mutation
-0.062 0.574 0.915 0.940 0.31-2.90
NIS (< 1+, 50%) 0.912 0.486 0.051 2.490 0.99-6.23
TSHR (< 2+) 1.702 0.484 <0.001 5.487 2.13-14.16
VEGF (< 3+) 1.082 0.470 0.021 2.951 1.17-7.42
VEGFR2 (< 2+) 1.107 0.485 0.022 3.025 1.17-7.83
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Variables B S.E p-value Odd Ratio 95% C.I
NF-κB 
(< 1+, 50%)
1.229
0.524
5
0.019 0.293 0.105-0.818
PTEN (negative) 0.671 0.536 0.211 1.955 0.68-5.59
Multivariate regression (stepwise selection)
Constant -7.854 2.517 0.002 0.000
TERT mutation 4.07 1.859 0.029 58.529 1.532-2235.634
Height/Width r
atio of tumor cell
(maximum ≥ 3)
3.717 1.481 0.012 41.143 2.259-749.405
Small clusters
(≥ 20%)
4.049 1.608 0.012 57.315 2.451-1340.483
Necrosis 5.407 1.862 0.004
223.06
7
5.803-8574.022
TSHR (<2+) 2.870 1.569 0.067 17.629 0.815-381.453
VEGFR2 (<2+) 2.617 1.553 0.092 13.692 0.653-287.180
Logistic regression analysis was performed in radioiodine-refractory (N = 26) 
and radioiodine-responsive (N = 82) cases of PTC, using all available 
features. CI, confidence intervals; 1small tumor clusters composed of 
micropapillae without fibrovascular cores; 2 the tumor cells show a granular 
eosinophilic cytoplasm with a height is at least triple their width (< 50% of 
tumor); NIS, sodium iodide symporter; TSHR, thyroglobulin stimulating 
hormone receptor; VEGF, vascular endothelial cell growth factor; VEGFR2, 
vascular endothelial cell growth factor receptor 2; NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells. 
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IV. DISCUSSION
In this study, we find out that an increased frequency of small clusters or 
hobnail features in tumors and the presence of small clusters or hobnail features 
especially in tumor centers were significant predictor of RI-refractoriness in 
PTCs. 
The prognosis for PTCs is generally favorable. However, some variants of 
PTCs, including the tall cell, columnar, diffuse sclerosing, and solid variants, 
are associated with more aggressive clinical features. 46 A recently described, 
new variant of PTC exhibiting > 30% micropapillary or hobnail feature in 
tumor cells demonstrates discohesive growth and single cells with a loss of 
polarity. In this variant, nuclei show characteristic apical placement and bulging 
out to surface.47,48 This rare hobnail variant is associated with a higher mortality 
rate than classic PTC, and is associated with frequent lymph node metastasis, 
recurrence, and distant metastasis.48 A recent study reported that PTC can be 
considered to have hobnail features if the hobnail component comprises at least 
10% of the tumor. Although the proportion of hobnail or small clusters is lower 
than 30% of PTC, it is significantly associated with poor prognosis. In one case 
study, small clusters or a hobnail component were most often found especially 
at the tumor-infiltrating edge or periphery.48 Similarly, in this study, the 
frequency of small clusters or hobnail features in tumors and the presence of 
small clusters or hobnail features in tumor centers were significantly higher in 
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RI-refractory PTC than in RI-responsive PTCs. 
Additionally, we suggest that an increased maximum height/width ratio in 
tumor cells (≥3) in non-tall cell variant PTC could predict RI-refractoriness.
The tall cell variant of PTC also shows aggressive behavior, similar to the 
hobnail variant. Histologically, ≥50% of the tumor cells show a granular 
eosinophilic cytoplasm with a height is at least triple their width. However, in 
recent case studies, a ≥10% cut–off threshold for tall cell quantity has been 
suggested to be strongly associated with a poorer clinical outcome.49 Here, we 
showed that a higher (≥3) maximum height/width ratio of tumor cells in the 
non-tall cell variant of PTCs was were significantly associated with 
RI-refractory PTC and predict of RI-refractoriness. These data support its use as 
a prognostic factor of aggression in PTC. TERT promoter mutations in the tall 
cell variant have recently been found to be a strong predictor of tumor 
relapse.37-39 TERT promoter mutation and maximum height/width ratio of tumor 
cells (≥3) were also found to be significantly associated in this study.
Immunohistochemically, the decreased expression of NIS and TSHR observed 
in this study suggests that impairment of the iodide-handling machinery, and it 
may be associated with RI refractoriness.
Transportation of iodide through the sodium–iodide symporter (NIS) is 
up-regulated by TSH-mediated activation of TSHR.26 In previous studies, NIS
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protein was found to be expressed in the cytoplasm rather than the cytoplasmic 
membrane of cancer cells,50 and the intracellular expression of NIS protein 
might be related to its inactivation, due to intracellular migration.51 In this study, 
the NIS protein was expressed mostly in the intranuclear portion of tumor cells, 
but it was strongly expressed in the intracellular or basolateral membrane in 
normal follicular cells. No staining was observed in the lung or liver tissue used 
as negative controls. According to a recent study of expression of NIS in 
different PTC variants, strong intranuclear or nuclear membrane staining for 
NIS protein was observed in conventional PTCs, and staining for NIS protein 
was negative (0 and 1+) in the tall cell and diffuse sclerosing variants of PTC, 
which are considered to be aggressive subtypes of PTC.31 In advanced thyroid 
cancers, failure of RI treatment may be associated with impairment of the 
iodide- handling machinery.9 Similarly, we observed the decreased expression 
of NIS and TSHR in RI-refractory PTC, and we suggest that impairment of the 
iodide-handling machinery may be associated with RI refractoriness.
The aggressive behavior of TERT-mutated tumors may be associated with the
alteration of function of NIS and other genes, which leads to decreased RI 
avidity and failure of RI treatment. According to our results, impairment of NIS 
expression was correlated with TERT promoter mutation, but not with BRAF
V600E mutation. Concordant with our results, TERT promoter mutation was 
considered to be an independent predictor of distant metastases and disease 
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progression in DTC.36 
The impairment of the iodide-handling machinery may be associated with 
aberrant activation of the MAPK signaling pathway, especially in mutation of 
BRAF V600E, which was found to be associated with RI refractoriness in 
previous studies. 16,28-30 Although the expression of NIS protein was not 
correlated with BRAF V600E mutation in this study, overall observation of 
whole tumor sections may be required to observed this association, because of 
the heterogeneous expression of NIS in PTC and metastatic lymph nodes.28
The impairment of the iodide-handling machinery may also be associated with 
activation of the PI3K–AKT signaling pathway in human thyroid cancer cells.32
Although PTEN loss did not differ significantly between RI-refractory and 
RI-responsive PTC, further study of a large number of cases, with overall 
observation of whole tumor sections and evaluation of phosphorylated Akt 
expression may be require to determine this association.
The WNT-β-catenin pathway plays a well-established role in the regulation of 
cell growth and proliferation. Up-regulated β-catenin is translocated into the
nucleus where it triggers transcription of various tumor-promoting genes. 
Up-regulation of β-catenin has been found in 66% of anaplastic thyroid cancers 
and 25% of poorly differentiated cancers. The WNT–β-catenin pathway play an 
important role in determining the aggressiveness of thyroid tumors. 25 However, 
the expression of β-catenin was restricted to the cytoplasm of all cases of PTC
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observed in this study. This result supports the finding that activation of the 
WNT–β-catenin pathway is not observed in DTCs and is not associated with
aggressiveness.
Experimental and clinical studies of the relationship between VEGF in 
endothelial cells and TERT mutation have shown, that vascular degeneration is 
associated with down-regulation of TERT mRNA expression. Most studies 
reported that TERT plays an important role in VEGF-mediated angiogenesis, 
and TERT may act as a VEGF transcription factor.49 However, our study showed 
no significant association between TERT promoter mutation and expression of 
VEGF and VEGFR2. Although no significant associations were observed, the 
expression of VEGF in tumor cells was remarkably negative within the small 
clusters and faint in the hobnail components. These results suggest that it may 
be a clue to explaining the relationship between low expression of NIS and 
TSHR and the increased proportion of small clusters or hobnail components in 
RI-refractory PTC. 
Among the up-regulated oncogenic proteins, NF-κB has been revealed to play 
an important role in controlling proliferative activity and anti-apoptotic 
signaling pathways in thyroid cancer cells. In recent studies, NF-κB has been 
shown to play a major role in cell survival via synergic cross-talk with other 
oncogenic signaling pathways. Up-regulation of NF-κB has been shown to be 
associated with BRAF V600E mutation.22 Although the expression of NF-κB
43
was variably positive in both RI-refractory and RI-responsive PTCs, it was 
significantly lower in RI-refractory PTC than in RI-responsive PTC, in this 
study. 
Coexistence of the BRAF V600E and TERT C228T mutations was identified in 
the most aggressive subgroup of PTC; the combination was more significantly 
associated with the aggressive subgroup than either mutation alone.37 Our 
results also indicated that coexistence of the BRAF V600E and TERT mutations 
is significantly prevalent in RI-refractory PTC. 
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V. CONCLUSION
The following histopathologic features are characteristic of RI-refractory 
PTC: small tumor clusters or hobnail features in both the center and periphery 
of tumors, as well as tumor necrosis and increased frequency of TERT mutation. 
These features may help in predicting RI-refractoriness at diagnosis of PTC. 
Although it is difficult to formalize the results of multivariate logistic regression, 
our results suggest that these characteristic histologic features and TERT
mutation may play a critical role in diagnostic differentiation of PTCs and 
prediction of RI-refractoriness. 
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ABSTRACT (IN KOREAN)
갑상선 유두암에서 방사성요오드 치료 내성군의
유전자변이 및 조직학적 특징
<지도교수 홍 순 원 >
연세대학교 대학원 의학과
표 주 연
갑상선의 가장 흔한 악성 종양인 유두암은 최근 현저히
발생률이 증가하고 있지만 표준치료인 수술적 치료와 방사성
요오드 치료 및 갑상선 자극호르몬의 억제치료에 잘 반응한다. 
하지만 유두암 중 일부는 표준치료 후에도 재발하거나 원격
전이를 보이며 방사성요오드에 섭취가 안 되는 방사성요오드
치료 내성군으로 빠르게 진행하며, 이들 중에서는 미분화
갑상선암으로의 역분화를 보이기도 한다. 최근 갑상선암의
발생과 진행과 관련하여 분자생물학적인 연구의 비약적인
발전이 있어왔고, 가장 최근에는 염색체 끝분절(telomere)의
끝분절효소(telomerase)의 구성 요소인 역전사 요소(telomerase 
reverse transcriptase catalytic subunit, TERT)의 발현이
끝분절효소의 활성과 관련되어 있는 것이 보고되었다. TERT
promoter의 돌연변이가 확인되어 분화갑상선암에서보다 미분화
갑상선암에서 현저히 증가된다는 보고가 있었으며, BRAF V600E와
TERT C228T 돌연변이가 함께 있는 경우에는 따로 관여할 때
보다 암의 재발율이 현저히 증가하며 암의 공격적인 진행에
관여하는 것으로 보고되었다. 본 연구에서는 갑상선 유두암의
방사성요오드치료 내성군에서 임상조직학적인 특징과 BRAF
돌연변이 및 TERT promoter 돌연변이와 같은 유전적인 변화를
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확인해보고자 하였으며 방사성요오드치료 반응군과 비교
분석하여 치료 내성군의 고유한 특징을 찾고자 하였다. 
강남 세브란스 병원에서 갑상선 유두암으로 표준치료를 받은
환자들 중 방사성요오드 치료의 누적용량이 >600mCi 이면서
재발 또는 원격전이를 보여 치료 내성을 보인 환자 82명 중
조직 절편을 구할 수 있는 26명을 찾았고, 표준 치료 후 5년
동안 재발하거나 전이하지 않은 갑상선 유두암 환자 82명을
대조군으로 선정하였다.
병리조직학적 소견을 검토한 결과, 방사성요오드 치료
내성군은 종양의 내부와 변연부에서 혈관을 갖지 않은 작은
종양세포의 군집(small cluster)이 빈번히 보였으며 그 양도
치료 반응군에 비해 증가되어 있었다. 세포의 키가 커지고 징
모양으로 돌출하는 hobnail features도 치료 내성군에서 많이
관찰되었고 특히 종양의 중심부에서 높은 빈도로 관찰되었다. 
특이하게도, 치료 내성군에서 종양 세포의 세로길이가 길어진
(Height/Width ratio of tumor cell (maximum ≥ 3) 세포들이
빈번히 관찰되었고, 치료 내성군 내에서도 핵이 위치가 위, 
가운데, 아래쪽의 순서로 증가하며 분포하는 경향을 보였다. 
치료 내성군은 유사분열과 종양세포의 괴사소견도 대조군에
비해 높은 빈도로 관찰되었다. 유전자 검사 결과 치료
내성군에서 53.8% (14/26)에서 TERT promoter 돌연변이를
확인했고 치료 반응군에서는 오직 1예에서만 확인되었다. 두
군에서 BRAF V600E 돌연변이는 모두 80% 이상으로 확인되었고, 
전체 108예 중 13예는 TERT promoter와 BRAF 돌연변이가 모두
확인되었다. 조직학적 특징들은 TERT promoter 돌연변이와도
유의미한 연관성을 나타내었다. 갑상선 유두암의 분자유전학적
신호전달체계와 관련된 단백질에 대한 면역조직화학염색 결과,
요오드 섭취와 관련한 sodium-iodide symporter (NIS)와 갑상선
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자극 호르몬 수용체 (TSHR)의 발현, 혈관신생과 관련된
혈관내피세포성장인자 (VEGF)와 혈관내피세포성장인자 수용체
(VEGF2)의 발현, 세포분열 및 증식과 관련이 있는 nuclear 
factor kappa B (NF-κB)의 발현이 모두 치료 내성군에서 현저히
감소했다. NIS와 TSHR의 발현감소는 특히 방사성요오드 치료
내성과 관련이 있는 것으로 생각되며, 이들 단백의 발현 감소
정도와 조직학적 특징은 다양한 양상으로 음의 상관관계를
보였다. 방사성요오드 치료 내성군에서 의미 있게 관찰된
임상병리학적 및 분자유전학적 변수들은 회귀분석 결과, 
종양괴사, TERT 돌연변이, small clusters의 증가 (≥20%) 와
세포의 키 증가((Height/Width ratio of tumor cell 
(maximum≥3)를 보이는 경우 방사성요오드 치료 내성과
유의미한 연관성을 보였고 98.8%의 치료 내성의 양성 예측률을
보였다. 
본 연구를 통해 갑상선 유두암의 방사성요오드치료 내성과
관련한 유전자변이와 조직학적 특징을 확인했지만, 방사성
요오드 치료 내성의 진단기준 또는 나쁜 예후 인자로서의
기준으로 공식화하기는 어려웠다. 하지만, 추가 연구를 통해
갑상선 유두암의 진단 및 예후 예측에 적용될 수 있다면 이번
연구의 의미가 클 것이라 여겨진다.
-----------------------------------------------------------
핵심 되는 말: 갑상선 유두암, 방사성 요오드 치료 내성, TERT
promoter 돌연변이, hobnail, micropapillary
